Opioid Overdose and Intoxication

• Central respiratory depression: Mu-receptor activation in the brainstem chemoreceptor trigger zone and respiratory centers decreases ventilatory drive and blunts hypercapnic/hypoxic respiratory responses. Opioids suppress neurons in the pre-Bötzinger complex (primary respiratory rhythm generator) and pontine respiratory centers, resulting in decreased minute ventilation, increased apneic episodes, and profound hypoxia. This mechanism is dose-dependent and most critical in overdose; fentanyl and its synthetic analogs (carfentanil, isotonitazene) have dramatically higher potency and mu-receptor affinity, making overdose more likely with minimal dose increases.

• Miosis and CNS depression: Mu-activation in the oculomotor nucleus produces pinpoint pupils (miosis), which occurs preferentially over respiratory depression at lower doses but becomes obligate at severe toxicity levels. Central opioid effects include decreased consciousness ranging from drowsiness to unresponsiveness, with opioids directly depressing multiple CNS centers including the cerebral cortex, hypothalamus, and reticular activating system. The severity correlates with serum levels and receptor occupancy.

• Peripheral and hemodynamic effects: Opioids cause vasodilation and decreased sympathetic tone through mu-receptors in the vasomotor center and direct peripheral effects, leading to hypotension. Bradycardia results from vagal stimulation and direct SA nodal depression. Pulmonary edema (noncardiogenic) occurs through mu-receptor-mediated increased pulmonary capillary permeability and fluid transudation, exacerbated by negative pressure breathing during respiratory effort against closed airways.

• Gastrointestinal effects: Mu-receptor activation in the enteric nervous system decreases bowel motility and increases sphincter tone, contributing to constipation acutely visible as reduced bowel sounds; aspiration risk increases with loss of protective airway reflexes.

• Additional considerations: Novel synthetic opioids (fentanyl, carfentanil) exhibit rapid brain penetration due to high lipophilicity, faster onset than heroin, and prolonged duration potentially outlasting naloxone action. Concurrent benzodiazpin or alcohol exposure potentiates CNS and respiratory depression through synergistic CNS inhibition.

Major causes and risk factors

• Illicit/recreational opioid use: Heroin, fentanyl, fentanyl analogs (carfentanil, isotonitazene, xylazine-adulterated products), counterfeit pills containing fentanyl; overdose risk increases dramatically when purity is unknown or products are adulterated with highly potent synthetic opioids.

• Prescribed opioid medications: Morphine, oxycodone, hydrocodone, methadone, buprenorphine, transdermal fentanyl; risk elevated with dose escalation, concurrent CNS depressants, hepatic/renal insufficiency, or medication errors.

• Risk factors for severe overdose: Concurrent benzodiazpin or alcohol use (multiplicative CNS depression), sleep apnea or chronic pulmonary disease (baseline respiratory compromise), obesity, older age, hepatic cirrhosis (altered metabolism), renal insufficiency (metabolite accumulation), opioid use disorder with episodic abstinence followed by relapse (tolerance loss), recent incarceration or detoxification (tolerance loss), polysubstance use particularly with xylazine or benzodiazpines, and previous opioid overdose (marker of high-risk behavior and impaired overdose awareness).

• Accidental exposures: Transdermal fentanyl patch misuse (chewing, heating, applying to mucous membranes), pediatric accidental ingestion, occupational exposure (first responders, law enforcement handling illicit drugs), and therapeutic dosing errors in opioid-naive patients.

Cardinal symptoms and signs

• Altered consciousness: Ranges from mild sedation and difficulty concentrating to profound coma unresponsive to noxious stimuli; may manifest as sudden sleep ("nodding off") in recreational users or progressive unresponsiveness if oral ingestion.

• Respiratory depression (hallmark of severe intoxication): Decreased respiratory rate (<8-10 breaths/min), shallow tidal volumes, periodic breathing or apnea, hypoxia (SpO₂ <90%), hypercapnia (PaCO₂ >45 mmHg, often much higher in severe cases), and cyanosis; progression to complete apnea and cardiopulmonary arrest if untreated.

• Miosis (pinpoint pupils): Bilateral constricted pupils, typically <2mm, highly characteristic but may be absent if concurrent sympathomimetic exposure, severe hypoxia/anoxia, or seizures occur; absence does not exclude severe opioid overdose.

• Pulmonary edema: Frothy pink sputum, crackles/rales on auscultation, hypoxia out of proportion to initial clinical findings; typically noncardiogenic and ARDS-like, thought to result from mu-receptor-mediated increased pulmonary capillary permeability and negative-pressure pulmonary edema.

• Physical exam findings: Cool, clammy skin from vasodilation and possible shock; hypotension (systolic <90 mmHg in severe cases); bradycardia; injection sites with track marks, abscesses, or thrombophlebitis (evidence of IV use); decreased or absent bowel sounds; loss of pupillary light reflex and corneal reflex in profound coma; potential seizures (particularly with meperidine or tramadol toxicity, or from severe hypoxia).

• Timing of presentation: Heroin overdose typically manifests within minutes to 1-2 hours of IV injection, within 30 minutes of intranasal use, and 30-60 minutes of oral ingestion; fentanyl-related overdoses may present more rapidly; methadone or long-acting formulations show delayed onset (8-24 hours) and prolonged course.

• History and clinical presentation: Witness account of opioid use (specific drug, dose if known, time of ingestion, route), presence of drug paraphernalia (syringes, spoons, lighters), altered consciousness with miosis and respiratory depression form the diagnostic triad. Obtain timeline of symptom onset and any prior exposure or withdrawal episodes.

• Physical examination: Assess responsiveness to stimuli (Glasgow Coma Scale), respiratory rate and effort, oxygen saturation, blood pressure, heart rate, pupil size and reactivity, presence of pulmonary edema, and evidence of IV drug use.

• Pulse oximetry and capnography: SpO₂ typically <90-95% in moderate-to-severe overdose; end-tidal CO₂ may be markedly elevated (>60 mmHg) reflecting hypoventilation and CO₂ retention.

• Arterial or venous blood gas: Respiratory acidosis (elevated PaCO₂, decreased pH) with or without concurrent metabolic acidosis; PaCO₂ often 60-100+ mmHg in severe cases; hypoxemia (PaO₂ <60 mmHg on room air).

• Serum opioid screening and urine drug screen: Qualitative immunoassays (urine) detect morphine, codeine, and 6-monomorphine but do NOT detect fentanyl, synthetic opioid analogs (carfentanil, xylazine), or some prescription opioids; results do not guide acute management and may delay critical treatment. Quantitative serum opioid levels are rarely available acutely and do not correlate well with clinical severity. Useful primarily for confirmation in stable patients; toxicology is NOT required for diagnosis in classic presentations.

• Electrocardiogram: May reveal bradycardia; generally normal unless concurrent cardiac pathology or prolonged QT (as seen with some synthetic opioids like methadone or novel fentanyl analogs).

• Chest X-ray: Shows bilateral infiltrates consistent with pulmonary edema in patients with respiratory symptoms; may appear normal early.

• Lactate and metabolic panel: Elevated lactate from hypoperfusion and anaerobic metabolism (marker of shock); hyperkalemia may develop from rhabdomyolysis in prolonged hypoxia or crush injury (if patient found unresponsive for extended period).

• Differential diagnosis considerations: Benzodiazpin overdose (miosis less common, longer half-life), barbiturate toxicity, sedative-hypnotic overdose, CNS infection (meningitis/encephalitis), acute intracranial pathology, hypoglycemia, carbon monoxide poisoning, or combinations of the above; naloxone challenge can be diagnostic and therapeutic (see Treatment section).

Immediate management of opioid overdose is a medical emergency requiring rapid airway, breathing, and circulation stabilization.

First-line pharmacotherapy

• Naloxone (Narcan): Competitive mu-opioid receptor antagonist with rapid onset (IV: 1-2 minutes, intranasal: 3-5 minutes, IM: 5-15 minutes) and short half-life (30-90 minutes, often shorter than opioids). Dosing: Initial IV bolus 0.4-2 mg (typical starting dose 0.4 mg IV, increased by 0.4 mg every 2-3 minutes to maximum 10 mg if needed); intranasal 2-4 mg (0.1 mL of 40 mg/mL concentration) into one nostril, repeated every 2-3 minutes in alternate nostril; IM or subcutaneous 0.4-2 mg followed by additional doses. Mechanism: Competitively displaces opioids from mu-receptors, reversing respiratory depression, miosis, and CNS effects; does NOT reverse opioid-induced seizures or pulmonary edema independently. Key point: Naloxone may precipitate acute opioid withdrawal (agitation, tachycardia, hypertension, body aches, diaphoresis) but this is preferable to death; withdrawal is uncomfortable, not life-threatening. Duration and re-dosing: Because naloxone's half-life is shorter than many opioids (especially methadone, long-acting morphine, fentanyl patches), repeat doses every 20-90 minutes may be necessary; continuous IV infusion at 2/3 of the bolus dose that induced response can be used for prolonged monitoring. Novel fentanyl analogs (carfentanil) may require higher cumulative naloxone doses or continuous infusion.

• Airway management and bag-valve-mask ventilation: Do NOT delay naloxone administration to establish IV access; concurrent rescue breathing with high-flow oxygen and assisted ventilation are critical while preparing naloxone. Intubation should be performed if unable to maintain oxygenation/ventilation or protect airway; use rapid-sequence intubation with reduced induction agent doses in hypotensive patients. Post-intubation sedation and analgesia require careful dosing to avoid rebound respiratory depression when naloxone wears off.

• Oxygen and ventilatory support: Supplemental oxygen to target SpO₂ >94%; positive-pressure ventilation (CPAP/BiPAP) if responsive; mechanical ventilation if apneic or inadequate respiratory effort. Pulmonary edema may require aggressive diuresis (furosemide 40-80 mg IV) and positive-pressure ventilation (PEEP); however, avoid excessive IV fluids as pulmonary edema is typically noncardiogenic.

Second-line and adjunctive therapies

• Nalmefene: Long-acting opioid antagonist (half-life 8-10 hours) that is an alternative to naloxone, particularly useful when prolonged opioid effects are anticipated; dosing is 0.5-1 mg IV/IM/SC, with repeat dosing in 2-5 minutes if needed. Less commonly used acutely but prevents relapse into overdose after naloxone wears off.

• Benzodiazpines: Reserved for naloxone-precipitated withdrawal agitation or concurrent benzodiazpin dependency; lorazepam 1-4 mg IV or diazepam 5-10 mg IV can be used cautiously in alert patients but depress respiration further in overdose states.

• Seizure management: If seizures occur (from severe hypoxia, meperidine toxicity, or head trauma), lorazepam 2-4 mg IV or phenytoin; seizures typically resolve with oxygenation and naloxone reversal of CNS depression.

Non-pharmacological measures

• Supportive care: Monitor vital signs, pulse oximetry, and continuous cardiac telemetry; frequent reassessment as naloxone wears off; maintain normothermia (hypothermia is common and may mask severity; gradual rewarming if present).

• Position and aspiration precautions: Head-of-bed elevation to minimize aspiration risk if any altered consciousness persists; consider left lateral decubitus position if pulmonary edema develops.

• Prevent relapse: Do NOT discharge patient immediately after naloxone reversal; monitor for minimum 2-4 hours (many sources recommend 4 hours minimum, longer for long-acting opioids); counsel on overdose risk, offer medication for opioid use disorder (buprenorphine, methadone), and arrange addiction medicine consultation.

Monitoring and disposition

• ICU admission criteria: Altered consciousness despite naloxone, requirement for intubation/mechanical ventilation, severe respiratory depression, pulmonary edema, signs of shock, renal dysfunction (creatinine >2 mg/dL suggesting rhabdomyolysis from prolonged immobility), or use of long-acting opioids/novel fentanyl analogs.

• Ongoing monitoring: Serial blood gases, lactate, electrolytes, creatinine (rhabdomyolysis), creatine kinase if prolonged hypoxia; repeat naloxone dosing as needed; prepare for re-intubation if respiratory depression recurs.

• Discharge planning: Offer naloxone prescription for at-home use (intranasal or auto-injector kits), educate patient and family on overdose recognition and naloxone administration, provide opioid use disorder treatment (buprenorphine/methadone initiation in ED if available, or same-day outpatient linkage), and screen for depression/suicidality.

Acute complications during overdose and recovery

• Pulmonary edema (noncardiogenic/ARDS-like): Occurs in 5-10% of opioid overdoses; mechanism involves mu-receptor-mediated increased capillary permeability and negative-pressure pulmonary edema from forceful inspiratory effort against closed airways. Presents with frothy pink sputum, crackles, and hypoxia often out of proportion to initial respiratory depression. Management: high-flow oxygen, positive-pressure ventilation (CPAP/BiPAP/mechanical ventilation with PEEP 5-15 cm H₂O), judicious diuresis (furosemide 40-80 mg IV; however, avoid excessive IV fluids as fluid overload worsens pulmonary edema), and supportive care; mortality is low if aggressively managed but represents a common cause of morbidity.

• Rhabdomyolysis and acute kidney injury: Prolonged immobilization, crush injury from falls, or severe hyperthermia during overdose causes muscle breakdown with myoglobinuria; CK may exceed 10,000-100,000 U/L. Risk of acute tubular necrosis and hyperkalemia-induced arrhythmias. Management: aggressive IV hydration (goal urine output 200-300 mL/hour), urinary alkalinization with sodium bicarbonate infusion (target

• The toxidrome: pinpoint pupils + bradypnea + depressed consciousness. Of these, hypoventilation — not miosis — is the finding that kills and the one that best predicts opioid toxicity; a respiratory rate under about 12/min in a stuporous patient is the classic stem clue. Miosis can be absent with meperidine, with co-ingested sympathomimetics/anticholinergics, or after anoxic injury.

• Single best next step: open the airway and ventilate with bag-valve-mask and oxygen while giving naloxone. The 2020 AHA guidelines for opioid-associated emergencies stress that ventilation precedes and accompanies antagonist therapy. Never delay for a urine drug screen, head CT, or IV access (IM/intranasal routes work).

• Titrate naloxone to adequate ventilation, not to full alertness — overshooting precipitates withdrawal, vomiting with aspiration risk, and catecholamine surge that can worsen noncardiogenic pulmonary edema.

• Half-life mismatch is the tested trap: naloxone outlasts nothing. Methadone, sustained-release oxycodone, transdermal fentanyl, and carfentanil all outlive it, so the "awakened" patient who re-sedates in the hall needs redosing or an infusion, plus prolonged observation.

Associations examiners love

• Meperidine → normeperidine accumulation (worse in renal failure) → seizures; with MAOIs or serotonergic drugs → serotonin syndrome (hyperreflexia, clonus, mydriasis — the opposite pupils). Tramadol also lowers seizure threshold. Methadone → QT prolongation and torsades.

• Buprenorphine is a partial agonist with a ceiling on respiratory depression; overdose in a naive patient or child may need larger cumulative naloxone doses.

Common distractors

• Clonidine (and other alpha-2 agonists, including xylazine adulterating street fentanyl) mimics the toxidrome exactly — miosis, bradypnea, bradycardia, hypotension — but responds poorly to naloxone. Pontine hemorrhage and organophosphate poisoning also give pinpoint pupils; the latter adds SLUDGE and fasciculations.

• Do not give flumazenil for undifferentiated coma or mixed overdose — it can unmask seizures.

• Naltrexone is not a rescue drug; it is long-acting maintenance therapy. Discharge planning should include take-home naloxone and offer of buprenorphine or methadone, which CDC's 2022 opioid prescribing guideline and SAMHSA endorse as mortality-reducing.